Switzerland

Swiss pharma faces potentially huge losses from US policy shifts

An industry-backed study warns that changes in US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040 through weaker growth and possible relocation of production. The article should clearly distinguish the study’s scenarios from established forecasts and examine the stakes for jobs, exports and patients.